Fennec Pharmaceuticals (FENC) Accumulated Expenses (2010 - 2025)
Fennec Pharmaceuticals posted quarterly Accumulated Expenses of $5.6 million for Q4 2025, up 343.35% year-on-year from $1.3 million in Q4 2024, and up 343.35% on a QoQ basis from $1.3 million in Q3 2025.
Fennec Pharmaceuticals (FENC) has 16 years of Accumulated Expenses data on file, last reported at $5.6 million in Q4 2025.
- For the quarter ending Q4 2025, Accumulated Expenses rose 343.35% year-over-year to $5.6 million; the trailing twelve-month figure through Dec 2025 stood at $5.6 million (up 343.35% YoY), and the FY2025 full-year result was $5.6 million, up 343.35% from the prior year.
- Accumulated Expenses for Q4 2025 stood at $5.6 million, up from $1.3 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $5.6 million in Q4 2025 and bottomed at $171000.0 in Q2 2021.
- The 5-year median for Accumulated Expenses is $1.0 million (2023), against an average of $1.3 million.
- The widest annual swing landed in 2022, when Accumulated Expenses tumbled 70.35%; it then soared 368.85% in 2023.
- A 5-year view of Accumulated Expenses shows it stood at $877000.0 in 2021, then sank by 70.35% to $260000.0 in 2022, then jumped by 368.85% to $1.2 million in 2023, then climbed by 4.27% to $1.3 million in 2024, then surged by 343.35% to $5.6 million in 2025.
- The last three Accumulated Expenses figures came in at $5.6 million (Q4 2025), $1.3 million (Q3 2025), and $2.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Fennec Pharmaceuticals | 281.48 Mn | 244.70 Mn | 7.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.64 Mn |
| Sep 30, 2025 | 1.27 Mn |
| Jun 30, 2025 | 2.23 Mn |
| Mar 31, 2025 | 2.84 Mn |
| Dec 31, 2024 | 1.27 Mn |
| Sep 30, 2024 | 2.32 Mn |
| Jun 30, 2024 | 2.02 Mn |
| Mar 31, 2024 | 1.62 Mn |
| Dec 31, 2023 | 1.22 Mn |
| Sep 30, 2023 | 937,000.00 |
| Jun 30, 2023 | 773,000.00 |
| Mar 31, 2023 | 1.07 Mn |
| Dec 31, 2022 | 260,000.00 |
| Sep 30, 2022 | 394,000.00 |
| Jun 30, 2022 | 294,000.00 |
| Mar 31, 2022 | 412,000.00 |
| Dec 31, 2021 | 877,000.00 |
| Sep 30, 2021 | 860,000.00 |
| Jun 30, 2021 | 171,000.00 |
| Mar 31, 2021 | 384,000.00 |
| Dec 31, 2020 | 776,000.00 |
| Sep 30, 2020 | 201,000.00 |
| Jun 30, 2020 | 435,000.00 |
| Mar 31, 2020 | 232,000.00 |
| Dec 31, 2019 | 659,000.00 |
| Sep 30, 2019 | 117,000.00 |
| Jun 30, 2019 | 125,000.00 |
| Mar 31, 2019 | 153,000.00 |
| Dec 31, 2018 | 605,000.00 |
| Sep 30, 2018 | 210,000.00 |
| Jun 30, 2018 | 138,000.00 |
| Mar 31, 2018 | 140,000.00 |
| Dec 31, 2017 | 622,000.00 |
| Sep 30, 2017 | 165,000.00 |
| Jun 30, 2017 | 94,000.00 |
| Mar 31, 2017 | 132,000.00 |
| Dec 31, 2016 | 125,000.00 |
| Sep 30, 2016 | 88,000.00 |
| Jun 30, 2016 | 50,000.00 |
| Mar 31, 2016 | 81,000.00 |
| Dec 31, 2015 | 92,000.00 |
| Sep 30, 2015 | 86,000.00 |
| Jun 30, 2015 | 49,000.00 |
| Mar 31, 2015 | 45,000.00 |
| Dec 31, 2014 | 132,000.00 |
| Sep 30, 2014 | 38,000.00 |
| Jun 30, 2014 | 36,000.00 |
| Mar 31, 2014 | 57,000.00 |
| Dec 31, 2013 | 132,000.00 |
| Sep 30, 2013 | 65,000.00 |
| Jun 30, 2013 | 65,000.00 |
| Mar 31, 2013 | 92,000.00 |
| Dec 31, 2012 | 423,000.00 |
| Sep 30, 2012 | 87,000.00 |
| Jun 30, 2012 | 173,000.00 |
| Mar 31, 2012 | 38,000.00 |
| Dec 31, 2011 | 52,000.00 |
| Sep 30, 2011 | 62,000.00 |
| Jun 30, 2011 | 31,000.00 |
| Dec 31, 2010 | 195,000.00 |